Arcturus Therapeutics (ARCT) Posts Quarterly Earnings Results, Beats Expectations By $0.41 EPS

Arcturus Therapeutics (NASDAQ:ARCT) posted its earnings results on Monday. The biotechnology company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.41, MarketWatch Earnings reports. The company had revenue of $7.58 million during the quarter, compared to the consensus estimate of $3.59 million.

NASDAQ:ARCT traded up $0.17 during trading hours on Tuesday, reaching $5.47. The company had a trading volume of 722 shares, compared to its average volume of 55,977. Arcturus Therapeutics has a 52 week low of $4.11 and a 52 week high of $10.00. The company has a market cap of $53.72 million, a PE ratio of -1.49 and a beta of 2.11.

A number of research firms have commented on ARCT. Chardan Capital reaffirmed a “buy” rating and issued a $18.00 target price on shares of Arcturus Therapeutics in a research report on Tuesday. Zacks Investment Research raised shares of Arcturus Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday. Laidlaw began coverage on shares of Arcturus Therapeutics in a research report on Tuesday, February 19th. They issued a “buy” rating for the company. ValuEngine downgraded shares of Arcturus Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 21st. Finally, Roth Capital reaffirmed a “buy” rating on shares of Arcturus Therapeutics in a research report on Wednesday, February 20th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $11.63.

WARNING: This story was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.dispatchtribunal.com/2019/03/19/arcturus-therapeutics-arct-posts-quarterly-earnings-results-beats-expectations-by-0-41-eps.html.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Ltd., an RNA medicines company, develops nucleic acid medicines to treat diseases with unmet medical needs. Its RNA therapeutics platforms could be applied in various types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA, and gene editing therapeutics.

Featured Story: What economic reports are most valuable to investors?

Earnings History for Arcturus Therapeutics (NASDAQ:ARCT)

Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.